Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-227 bioequivalence study in healthy volunteers
NCT06884085Phase 1Completed
- Sponsor
- Addpharma, Inc.
- Start
- Jul 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AD-227 in hypertension (HTN) (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Maximum Plasma Concentration at 72 hours and Area Under the Plasma Concentration-Time Curve During Dosing Interval at 72 hours. Started Jul 2025; status: completed.
02
Drugs
AD-227
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06884085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06884085.